Randomized, controlled, double-blind trial of taranabant for smoking cessation

Psychopharmacology

Volumn 209, Issue 3, 2010, Pages 245-253

  Morrison, Mary F ^a,b   Ceesay, Paulette ^a   Gantz, Ira ^a   Kaufman, Keith D ^a   Lines, Christopher R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Cannabinoid 1 receptor inverse agonist; Randomized clinical trial; Smoking cessation; Taranabant

Indexed keywords

PLACEBO; TARANABANT;

ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASTHENIA; BACKACHE; BASAL CELL CARCINOMA; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; CRYING; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GLUCOSURIA; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTRIGLYCERIDEMIA; IRRITABILITY; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MELANOMA; MENTAL INSTABILITY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING CESSATION; THORAX PAIN; TOBACCO DEPENDENCE; TONGUE PAPILLA HYPERTROPHY; VOMITING; WEIGHT CHANGE;

ADOLESCENT; ADULT; AGED; AMIDES; BEHAVIOR, ADDICTIVE; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INVERSE AGONISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; RECEPTOR, CANNABINOID, CB1; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 77953285558     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1790-2     Document Type: Article

References (27)

1. Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L et al (2008a) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 48: 418-427 [Epub 2008 Feb 7] (Pubitemid 351389116)
2. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ et al (2008b) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7: 68-78
3. Akbas F, Gasteyger C, Sjödin A, Astrup A, Larsen TM (2009) A. critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10: 58-67 [Epub 2008 Aug 20]
4. Alberg AJ (2008) Cigarette smoking: health effects and control strategies. Drugs Today (Bare) 44: 895-904
5. Cahill K, Ussher M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (4):CD005353
6. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713 (Pubitemid 350100788)
7. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L et al (2008) Pharmacotherapies for smoking cessation: a metaanalysis of randomized controlled trials. CMAJ 179: 135-144 (Pubitemid 352020119)
8. European Medicines Agency (2006) Acomplia: scientific discussion. European Medicines Agency Web site. http://www.emea.europa. eu/humandocs/PDFs/ EPAR/acomplia/H-666-en6.pdf. Accessed 15 Oct 2009
9. Filozof C, Fernández Pinilla MC, Fernández-Cruz A (2004) Smoking cessation and weight gain. Obes Rev 5: 95-103
10. Forget B, Coen KM, Le Foll B (2009) Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB(1) receptor blockade. Psychopharmacology 205: 613-624
11. Gantz I, Erondu N, Suryawanshi A, Musser B, Nayee J, JohnsonLevonas AO et al (2008) A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. J Am Coll Cardiol 51(10 Suppl A): 326 (Abstract 1021-220)
12. Hughes JR, Keely J, Naud S (2004) Shape of the relapse curve and longterm abstinence among untreated smokers. Addiction 99: 29-38 (Pubitemid 38142221)
13. Izzo AA, Courts AA (2005) Cannabinoids and the digestive tract. Handb Exp Pharmacol 168: 573-598
14. Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16: 606-613 (Pubitemid 32823891)
15. Lancaster T, Stead L, Cahill K (2008) An update on therapeutics for tobacco dependence. Expert Opin Pharmacother 9: 15-22
16. Le Foll B, Goldberg SR (2005) Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312: 875-883 [Epub 2004 Nov 3] (Pubitemid 40293744)
17. Le Foll B, Forget B, Aubin HJ, Goldberg SR (2008) Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from, pre-clinical and clinical studies. Addict Biol 13: 239-252 (Pubitemid 351692986)
18. Le Foll B, Gorelick DA, Goldberg SR (2009) The future of endocannabinoid-oriented clinical research after CB(1) antagonists. Psychopharmacology (Berl) 205: 171-174 [Epub 2009 Mar 20]
19. Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV (2009) Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61: 217-224
20. Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H et al (2006) Discovery of N-[(1 S, 2 S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl] -2-methyl-2- {[5-(trifluoromethyl)pyridin2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49: 7584-7587 (Pubitemid 46033647)
21. Nides M (2008) Update on pharmacologic options for smoking cessation treatment. Am J Med 121(4 Suppl 1): S20-S31 (Pubitemid 351395277)
22. Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ 335: 1194-1199 (Pubitemid 350273303)
23. Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, Di Marino ME (2000) Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 95(8): 1185-1195 (Pubitemid 30644104)
24. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychoparmacology 166: 343-350 (Pubitemid 36469936)
25. Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 282: 1737-1744
26. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38: 177-188 (Pubitemid 40779571)
27. Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology (Berl) 169: 115-134 [Epub 2003 Jun 24] (Pubitemid 37129963)